Eculizumab
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Eculizumab. This is a complement C5 inhibitor. Fully referenced neurology checklist.
Pharmacology
- This is a complement C5 inhibitor
- It is indicated as rescue therapy in refractory myasthenia gravis (MG)
Dosing
Locked: subscribe to see this section.
Precautions
Locked: subscribe to see this section.
Benefits
Locked: subscribe to see this section.
Frequent adverse events
Locked: subscribe to see this section.
Treatment-resistance
Locked: subscribe to see this section.
References
- Kang C. Ravulizumab: a review in generalised myasthenia gravis. Drugs 2023; 83:717-723.
- Nair SS, Jacob S. Novel immunotherapies for myasthenia gravis. Immunotargets Ther 2023; 12:25-45.
- Sánchez-Tejerina D, Sotoca J, Llaurado A, López-Diego V, Juntas-Morales R, Salvado M. New targeted agents in myasthenia gravis and future therapeutic strategies. J Clin Med 2022; 11:6394.Vanoli F, Mantegazza R. Ravulizumab for the treatment of myasthenia gravis. Expert Opin Biol Ther 2023; 23:235-241.
- Waheed W, Newman E, Aboukhatwa M, Moin M, Tandan R. Practical management for use of eculizumab in the treatment of severe, refractory, non-thymomatous, AChR + generalized myasthenia gravis: a systematic review. Ther Clin Risk Manag 2022; 18:699-719.
